Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (Immunomodulatory Treatment of Early-onset MS) study group

被引：0
|
作者：
Ghezzi, A
Amato, MP
Gallo, P
Marrosu, MG
Martinelli, V
Milani, N
Milanese, C
Moiola, L
Patti, F
Pozzilli, C
Trojano, M
Zaffaroni, M
Pilato, V
Comi, G
机构：
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [41] Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
    Oreja-Guevara, Celia
    Martinez-Yelamos, Sergio
    Eichau, Sara
    Llaneza, Miguel Angel
    Martin-Martinez, Jesus
    Pena-Martinez, Joaquin
    Meca-Lallana, Virginia
    Alonso-Torres, Ana Maria
    Moral-Torres, Ester
    Rio, Jordi
    Calles, Carmen
    Ares-Luque, Adrian
    Ramio-Torrenta, Lluis
    Marzo-Sola, Maria Eugenia
    Prieto, Jose Maria
    Martinez-Gines, Maria Luisa
    Arroyo, Rafael
    Otano-Martinez, Maria Angeles
    Brieva-Ruiz, Luis
    Gomez-Gutierrez, Montserrat
    Rodriguez-Antiguedad, Alfredo
    Sanchez-Seco, Victoria Galan
    Costa-Frossard, Lucienne
    Hernandez-Perez, Miguel Angel
    Landete-Pascual, Lamberto
    Gonzalez-Platas, Montserrat
    Meca-Lallana, Jose E.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [42] Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis
    Edwards, Natalie C.
    Munsell, Michael
    Menzim, Joseph
    Phillips, Amy L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1389 - 1395
  • [43] Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy
    Curkendall, Suellen M.
    Wang, Cheng
    Johnson, Barbara H.
    Cao, Zhun
    Preblick, Ronald
    Torres, Amelito M.
    Knappertz, Volker
    Gondek, Kathleen
    CLINICAL THERAPEUTICS, 2011, 33 (07) : 914 - 925
  • [44] Disease-modifying drugs in relapsing-remitting multiple sclerosis: evidence-based treatment algorithm for Latin America
    Finkelsztejn, A.
    Gabbai, A. A.
    Fragoso, Y. D.
    Carra, A.
    Macias-Islas, M. A.
    Arcega Revilla, R.
    Garcia Bonitto, J.
    Oehninger Gatti, C. L.
    Orozco Escobar, G.
    Tarulla, A.
    Vergara, F.
    Vizcarra, D.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S452 - S453
  • [45] Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study
    Kreiter, Daniel
    Spee, Romy
    Merry, Audrey
    Hupperts, Raymond
    Gerlach, Oliver
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [46] Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a:: long-term results
    Ghezzi, A.
    Amato, M. P.
    Capobianco, M.
    Gallo, P.
    La Mantia, L.
    Marrosu, M. G.
    Martinelli, V.
    Milani, N.
    Milanese, C.
    Moiola, L.
    Patti, F.
    Pozzilli, C.
    Trojano, M.
    Zaffaroni, M.
    Comi, G.
    NEUROLOGICAL SCIENCES, 2007, 28 (03) : 127 - 132
  • [47] Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results
    A. Ghezzi
    M. P. Amato
    M. Capobianco
    P. Gallo
    M. G. Marrosu
    V. Martinelli
    C. Milanese
    L. Moiola
    N. Milani
    L. La Mantia
    F. Patti
    C. Pozzilli
    M. Trojano
    G. Comi
    M. Zaffaroni
    Neurological Sciences, 2007, 28 : 127 - 132
  • [48] Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
    Becker, Russell V., III
    Dembek, Carole
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (05): : 377 - 381
  • [49] The use of evidence-based medicine (EBM) to assess the benefit-to-risk of disease-modifying drugs (DMDs) in multiple sclerosis (MS)
    Chofflon, M
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S206 - S207
  • [50] PREFERENCES TOWARD ATTRIBUTES OF DISEASE-MODIFYING THERAPIES: THE ROLE OF NURSES IN MULTIPLE SCLEROSIS CARE (DECISIONS-MS STUDY)
    Munoz, B.
    Medrano, N.
    Azanza-Munarriz, C.
    Becerril-Rios, N.
    Goicochea-Briceno, H.
    Horno, R.
    Lendinez-Mesa, A.
    Sanchez-Franco, C.
    Alvarez, C.
    Carreno, A.
    Sarmiento, M.
    Bueno-Gil, G.
    Maurino, J.
    VALUE IN HEALTH, 2022, 25 (01) : S37 - S37
12345